Clinical Trial Update: Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911) [Phase 3]

View source ↗

Summary

Phase 3 study results assess safety, tolerability, and immunogenicity of co-administering V110 or V114 with a booster dose of mRNA-1273 in healthy adults.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infection

Drugs mentioned

• V110
• V114 (15-valent pneumococcal conjugate vaccine)
• mRNA-1273

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Pneumococcal Infection | Phase 3 | Status: COMPLETED | Results posted: 2024-02-13